Neumedicines Inc., a privately held biotechnology company, announced today that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense office of the Congressionally Directed Medical Research ... (more)
http://ift.tt/1iv78Pv
http://ift.tt/1iv78Pv
No comments:
Post a Comment